Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Molecular Partners AG    MOLN   CH0256379097

MOLECULAR PARTNERS AG (MOLN)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
01/15/2018 01/16/2018 01/17/2018 01/18/2018 01/19/2018 Date
27.2(c) 27(c) 25.8(c) 25.15(c) 25.25(c) Last
4 888 10 686 24 573 26 394 6 434 Volume
+0.74% -0.74% -4.44% -2.52% +0.40% Change
More quotes
Financials ( CHF)
Sales 2017 22,9 M
EBIT 2017 -28,5 M
Net income 2017 -28,3 M
Debt 2017 -
Yield 2017 -
Sales 2018 21,7 M
EBIT 2018 -38,6 M
Net income 2018 -38,1 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 23,1x
Capi. / Sales2018 24,4x
Capitalization 529 M
More Financials
Company
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders.It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to... 
More about the company
Surperformance© ratings of Molecular Partners AG
Trading Rating : - Investor Rating :
More Ratings
Latest news on MOLECULAR PARTNERS AG
01/08 Molecular Partners reports promising initial safety and efficacy data from it..
01/08 MOLECULAR PARTNERS AG : Molecular Partners Reports Promising Initial Safety and ..
01/04 MOLECULAR PARTNERS : Patent Issued for Modified Binding Proteins Inhibiting the ..
01/04 MOLECULAR PARTNERS AG : Molecular Partners to Present at The 36th Annual J.P. Mo..
01/03 Molecular Partners’ collaboration partner Allergan exercises options fo..
01/03 MOLECULAR PARTNERS' : Collaboration Partner Allergan Exercises Options for Two D..
01/03 MOLECULAR PARTNERS AG : Molecular Partners' Collaboration Partner Allergan Exerc..
01/03 MOLECULAR PARTNERS : rsquo; collaboration partner Allergan exercises options for..
2017 MOLECULAR PARTNERS : Study Findings from Molecular Partners AG Provide New Insig..
2017 Molecular Partners expands and advances robust pipeline of DARPin® therapies ..
More news
Sector news : Bio Therapeutic Drugs
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Bio Therapeutic Drugs
Latest Tweets
01/08Molecular Partners reports promising initial safety and efficacy data from it.. 
01/08Molecular Partners AG : Molecular Partners Reports Promising Initial Safety a.. 
01/03Molecular Partners AG : Molecular Partners' Collaboration Partner Allergan Ex.. 
2017Molecular Partners Publishes Invitation to Extraordinary General Meeting to b.. 
2017Molecular Partners provides additional details on clinical studies of proprie.. 
More tweets
Qtime:24
Chart MOLECULAR PARTNERS AG
Duration : Period :
Molecular Partners AG Technical Analysis Chart | MOLN | CH0256379097 | 4-Traders
Technical analysis trends MOLECULAR PARTNERS AG
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 38,5  CHF
Spread / Average Target 53%
EPS Revisions
Managers
NameTitle
Patrick Amstutz Chief Executive Officer & Director
Jörn Aldag Chairman
Andreas Emmenegger Chief Financial Officer
Michael Tobias Stumpp Chief Scientific Officer
Andreas Harstrick Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
MOLECULAR PARTNERS AG-4.37%553
GILEAD SCIENCES14.10%106 002
REGENERON PHARMACEUTICALS-0.50%39 890
VERTEX PHARMACEUTICALS4.76%39 754
GENMAB10.50%11 455
BLUEBIRD BIO INC2.25%8 346